Patient Age Predicts the Delay before Survivors of Cancer Utilise Their Cryopreserved Sperm for Assisted Reproductive Technology

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4481-4481
Author(s):  
Amit Patel ◽  
Thomas Stroud ◽  
Danielle Breen ◽  
Ala Taifoor ◽  
Anne Bradshaw ◽  
...  

Abstract Objective: Sperm cryopreservation (sperm banking) is the recommended standard of care for fertility preservation for men with cancer. Men can utilise their sperm for assisted reproductive technology (ART) when they are ready to become fathers. However, the duration of sperm cryopreservation that should be offered to men is unknown. We hypothesised that younger men with cancer require a longer duration of sperm storage before readiness to utilise their samples for ART, compared with older patients. To test this hypothesis, we investigated whether age at sperm harvest predicts the time of sperm storage necessary before ART. Design: A retrospectively analysed cohort study spanning 37 years using prospectively acquired routine clinical data. Setting: A specialist andrology facility in the UK, that provides unlimited storage of sperm as part of NHS treatment free-of-charge to the patient. Participants: Adolescent boys and men with a confirmed diagnosis of cancer were identified by cross-referencing and verifying patient records: Human Fertility & Embryology Authority (HEFA), Department of Andrology, and the NHS Spine Services Portal database, part of the Health and Social Care Information Centre. Main outcome measures: The primary outcome measures were the effect of age on the time from sperm cryopreservation to use for ART, and the specificity and sensitivity of age at predicting the requirement of >10 years sperm storage. Results: 4305 men harvested and cryopreserved their sperm between 1976 and 2013. Men with cancer comprised 3191 and were included in the study. The cancer types that indicated sperm cryopreservation comprised testicular (1130, 35.4%), lymphoma (762, 23.9%), leukaemia (462, 14.5%), and others (838, 26.3%). At sperm harvesting, their median age was 30.3 years (IQR 24.6 to 36.2). Sperm from 217 (6.8%) patients with a median age of 31.3 (IQR 26.5 to 36.7) were utilized for ART after a median of 7.8 years (interquartile range (IQR) 3.5 to 14.3). Increasing age (HR=1.02, 95% CI 1.01 to 1.04, P=0.001), or age decile compared to ≤20 years (P=0.003), was associated with a reduced time interval to sperm utilisation. Age at harvest (P=0.006) was robust to multivariate Cox models (including cancer diagnosis, survival, and year of harvest) and sensitivity analyses. Age ≤30 years at sperm harvest was highly specific (86.1%) and sensitive (65.0%) at predicting the requirement for over ten years of sperm storage prior to ART (AUC 0.82, 95% CI 0.74 to 0.90, P<0.0001). Conclusions: Age at sperm cryopreservation is a key predictor for the likely storage duration necessary prior to ART in men with cancer. A policy of fixed duration of sperm storage may disproportionately deny young patients with cancer access to ART. Policies on sperm storage duration in this population should be reviewed. Disclosures No relevant conflicts of interest to declare.

Andrologia ◽  
2017 ◽  
Vol 50 (1) ◽  
pp. e12833 ◽  
Author(s):  
A. Reignier ◽  
J. Lammers ◽  
C. Splingart ◽  
D. Redhead ◽  
J. J. Labat ◽  
...  

2014 ◽  
Vol 73 (3) ◽  
pp. 150-153
Author(s):  
Chuyu Hayashi ◽  
Kaori Matsumoto ◽  
Erina Kato ◽  
Go Ichikawa ◽  
Fumihisa Chishima ◽  
...  

Zygote ◽  
2012 ◽  
Vol 22 (2) ◽  
pp. 132-137 ◽  
Author(s):  
Dun-Gao Li ◽  
Yan Zhu ◽  
He-Ping Li ◽  
Xue-Jin Chen ◽  
Man-Xi Jiang

SummaryThe maintenance and preservation of strains of mice used in biomedical research presents a unique challenge to individual investigators and research institutions. The goal of this study was to assess a comprehensive system for mouse strain conservation through a combination of natural mating, sperm cryopreservation and assisted reproductive technology. Our strategy was based on the collection and cryopreservation of fresh epididymal sperm from male mice by semi-vasectomy; these mice were then naturally mated for breeding purposes. If no satisfactory results were obtained from natural breeding, then the cryopreserved sperm were used for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI); resultant embryos were then transferred into pseudopregnant-recipient female mice. Our results show that some semi-vasectomized mouse strains can be conserved by natural breeding, and that sterile males can be compensated for through the use of IVF and ICSI technology. As such, we believe this system is suitable for the purpose of strain conservation, allowing the continuation of natural breeding with the safeguard of assisted reproduction available.


2019 ◽  
Vol 34 (11) ◽  
pp. 2290-2296 ◽  
Author(s):  
D Vassard ◽  
L Schmidt ◽  
C H Glazer ◽  
J Lyng Forman ◽  
M Kamper-Jørgensen ◽  
...  

Abstract STUDY QUESTION Does hormone stimulation during assisted reproductive technology (ART) treatment increase the risk of ovarian cancer? SUMMARY ANSWER No increased risk of ovarian cancer was found among ART-treated women, with the exception of ART-treated women with endometriosis. WHAT IS KNOWN ALREADY Previous studies on the association between ovarian stimulation during ART and ovarian cancer have shown conflicting results. The risk of ovarian cancer varies according to the cause of infertility, and only a few studies on ART treatment and risk of ovarian cancer have had sufficient data to address this issue. Endometriosis has been linked to an increased risk of ovarian cancer. STUDY DESIGN, SIZE, DURATION Women undergoing ART treatment during 1994–2015 were registered in the Danish IVF register. Data were linked with data from the Danish Cancer Register and socio-demographic population registers using an individual person identification number assigned to people residing in Denmark. PARTICIPANTS/MATERIALS, SETTING, METHODS All women undergoing ART treatment were age-matched with a random sample of the female background population and followed for up to 22 years. After relevant exclusions, the population consisted of 58 472 ART-treated women and 625 330 untreated women, all with no previous malignancies. Ovarian cancer risk was assessed using multivariable cox regression analyses with adjustment for educational level, marital status, parity and treatment year. Results are shown as hazard ratios (HRs) with corresponding CIs. MAIN RESULTS AND THE ROLE OF CHANCE In total, 393 (0.06%) women were diagnosed with ovarian cancer during follow-up (mean 9.7 years). Women treated with ART had an increased risk of ovarian cancer (HR 1.20, 95% CI 1.10–1.31), which diminished over time. The increased risk was apparent among women with female factor infertility (HR 1.36, 95% CI 1.25–1.48), whereas no female factor infertility was associated with a lower risk (HR 0.87, 95% CI 0.76–1.00). The risk was increased among women with endometriosis (HR 3.78, 95% CI 2.45–5.84), whereas no increased risk was found among ART-treated women with polycystic ovary syndrome, other female causes of infertility and unexplained infertility. LIMITATIONS, REASONS FOR CAUTION The association between ART treatment and ovarian cancer is likely influenced by increased detection due to multiple ultrasound scans during ART treatment. WIDER IMPLICATIONS OF THE FINDINGS Undergoing ART treatment without the presence of endometriosis was not associated with an increased risk of ovarian cancer, which is reassuring. Whether ART treatment increases the risk of ovarian cancer among women with endometriosis needs further investigation. STUDY FUNDING/COMPETING INTEREST(S) This work was supported by a PhD grant to D.V. from the Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Funding for establishing the Danish National ART-couple II cohort was achieved from Ebba Rosa Hansen Foundation. The funders had no influence on data collection, analyses or results presented. The authors have no conflicts of interest to declare.


2021 ◽  
Vol 902 (1) ◽  
pp. 012036
Author(s):  
R Widyastuti ◽  
D N Pristihadi ◽  
S Prastowo ◽  
H Maheshwari ◽  
C Sumantri ◽  
...  

Abstract Pasundan cattle are native Indonesian cattle located in West Java, Indonesia. These cattle have a superior trait in reproductive performance although reared in extreme environmental conditions with low-quality of feed, and resistance to parasite diseases than other cattle breeds. However, the ability to maintain Pasundan cattle genetic diversity, avoiding inbreeding, keeping the population healthy, and high reproduction efficiency are among the significant challenges currently occurred. The application of assisted reproductive technology (ART) seems promising to overcome those challenges and would impact the efficiency of genetic diversity conservation and preservation. This review aims to present the possibility to use the available ART in Pasundan cattle. The ART reviewed are the advanced technology of sperm cryopreservation, sex selection, artificial insemination, and in vitro embryo production. The sperm cryopreservation combined with sperm sexing is the most promising technology to maximize the use of genetic material of Pasundan cattle. Moreover, sexed sperm would have a promising impact on artificial insemination and/or embryo production to increase the cattle population. Furthermore, to protect genetic diversity, it is possible to apply the artificial reproductive technique and sperm or embryos conservation for genetic utilization in the future.


Sign in / Sign up

Export Citation Format

Share Document